Mechanism of Action, Pharmacokinetics, Efficacy, and Safety of Transarterial Therapies Using Ethiodized Oil: Preclinical Review in Liver Cancer Models

Gaba, Ron C.; Schwind, Regina M.; Ballet, Sébastien

doi:10.1016/j.jvir.2017.09.025

Cited by 14 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipiodol is an embolizing agent that is particularly suited for chemo/radioembolization. When injected through the hepatic artery, it has been demonstrated to be selectively trapped into the tumor cells, where it displays a prolonged retention time, while being quickly eliminated from healthy liver cells [54,55]. Thus, the combination of Lipiodol embolization with Yttrium-90 irradiation seems attractive.…”

Section: Discussionmentioning

confidence: 99%

“…An amount of 1 mL of freshly prepared 90 Y-hinokitiol (45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64) in Lipiodol phase was taken with a syringe and put into a 12-mL flat bottom glass vial, containing 10 mL of physiological serum (previously weighed), and the vial was closed. Activity in the vial was measured with the dose calibrator.…”

Section: Over Time Release In the Aqueous Phasementioning

confidence: 99%

See 1 more Smart Citation

Labeling of Hinokitiol with 90Y for Potential Radionuclide Therapy of Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), the most common form of primary liver tumors, is the fifth cancer in the world in terms of incidence, and third in terms of mortality. Despite significant advances in the treatment of HCC, its prognosis remains bleak. Transarterial radioembolization with radiolabeled microspheres and Lipiodol has demonstrated significant effectiveness. Here we present a new, simple radiolabeling of Lipiodol with Yttrium-90, for the potential treatment of HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Over Time Release In the Aqueous Phasementioning

confidence: 99%

Labeling of Hinokitiol with 90Y for Potential Radionuclide Therapy of Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…At present, there are no available response evaluation criteria strategies for use in other large animal species, such as pigs. This fact is substantiated by the wide variation of response assessment methods used in published preclinical investigations (67), which span simple reporting of tumor diameter to description of percent tumor growth or involution, and which lack a common language for comparison across published studies. Development and validation of standardized tumor response assessment systems applicable in biomedical animal models represents an important barrier to broad employment of large animals in preclinical trials, and one which must be overcome if radiologic imaging is to be utilized for preclinical trial applications.…”

Section: Existing Response Assessment Schemes For Animal Clinical Oncmentioning

confidence: 99%

Radiologic Modalities and Response Assessment Schemes for Clinical and Preclinical Oncology Imaging

Faraji

Gaba

2019

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Clinical drug trials for oncology have resulted in universal protocols for medical imaging in order to standardize protocols for image procurement, radiologic interpretation, and therapeutic response assessment. In recent years, there has been increasing interest in using large animal models to study oncologic disease, though few standards currently exist for imaging of large animal models. This article briefly reviews medical imaging modalities, the current state-of-the-art in radiologic diagnostic criteria and response assessment schemes for evaluating therapeutic response and disease progression, and translation of radiologic imaging protocols and standards to large animal models of malignant disease.

show abstract

“…Small embolic particles coated with chemotherapeutic agents are injected selectively into an artery directly supplying the tumor thus targeting mostly HCC cells but not normal hepatocytes. In this regard, in animal models of HCC, trans arterial drug delivery resulted: (1) to be safe both for the liver and for distant organs, (2) to display preferential tumor uptake of the anti-cancer drug and (3) to have high tumor response [ 58 ]. With regard to the delivery of siRNA, an anti hypoxia-inducible factor-1α (HIF-1α-siHIF-1α) was released by a trans arterial embolization procedure complexed within a iodized oil emulsion [ 59 ].…”

Section: Specific Strategies To Optimize Sirna Delivery To Hccmentioning

confidence: 99%

Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness

et al. 2018

View full text Add to dashboard Cite

Despite the advances in anticancer therapies, their effectiveness for many human tumors is still far from being optimal. Significant improvements in treatment efficacy can come from the enhancement of drug specificity. This goal may be achieved by combining the use of therapeutic molecules with tumor specific effects and delivery carriers with tumor targeting ability. In this regard, nucleic acid-based drug (NABD) and particularly small interfering RNAs (siRNAs), are attractive molecules due to the possibility to be engineered to target specific tumor genes. On the other hand, polymeric-based delivery systems are emerging as versatile carriers to generate tumor-targeted delivery systems. Here we will focus on the most recent findings in the selection of siRNA/polymeric targeted delivery systems for hepatocellular carcinoma (HCC), a human tumor for which currently available therapeutic approaches are poorly effective. In addition, we will discuss the most attracting and, in our opinion, promising siRNA-polymer combinations for HCC in relation to the biological features of HCC tissue. Attention will be also put on the mathematical description of the mechanisms ruling siRNA-carrier delivery, this being an important aspect to improve effectiveness reducing the experimental work.

show abstract

Mechanism of Action, Pharmacokinetics, Efficacy, and Safety of Transarterial Therapies Using Ethiodized Oil: Preclinical Review in Liver Cancer Models

Cited by 14 publications

References 48 publications

Labeling of Hinokitiol with 90Y for Potential Radionuclide Therapy of Hepatocellular Carcinoma

Labeling of Hinokitiol with 90Y for Potential Radionuclide Therapy of Hepatocellular Carcinoma

Radiologic Modalities and Response Assessment Schemes for Clinical and Preclinical Oncology Imaging

Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness

Contact Info

Product

Resources

About